Table 2.

Performance of radiopathomics signature at each category

Metric (%) [95% CI]	Total (N = 678)	VC1 (N = 480)	VC2 (N = 150)	VC3 (N = 48)
ACC	85.25 [82.55–87.96]	87.76 [84.86–90.66]	79.71 [72.52–84.9]	81.24 [70.15–92.34]
Sensitivity (TRG0)	96.08 [92.98–99.18]	96.49 [93.03–99.95]	96.62 [89.92–100.0]	91.3 [74.73–100.0]
Sensitivity (TRG1)	65.53 [58.62–72.44]	62.59 [54.22–70.95]	75.57 [61.75–89.4]	63.39 [42.96–83.82]
Sensitivity (TRG2)	97.67 [95.93–99.4]	97.16 [95.02–99.29]	100.0 [100.0–100.0]	100.0 [100.0 100.0]
Sensitivity (TRG3)	35.69 [20.0–51.38]	–	35.55 [19.99–51.12]	–
PPV (TRG0)	93.68 [89.93–97.43]	94.58 [90.48–98.69]	93.52 [84.68–100.0]	83.09 [61.19–100.0]
PPV (TRG1)	85.81 [80.03–91.59]	92.02 [86.19–97.85]	70.26 [56.42–84.1]	93.57 [81.1–100.0]
PPV (TRG2)	81.36 [77.32–85.39]	83.9 [79.6–88.19]	74.24 [63.57–84.92]	71.49 [52.04–90.94]
PPV (TRG3)	86.67 [69.29–100.0]	–	92.54 [78.21–100.0]	–

Statistical quantifications shown with 95% CI, when applicable

TRG tumor regression grade, VC1 validation cohort 1, VC2 validation cohort 2, VC3 validation cohort 3, PPV positive predictive value, ‘–’ insufficient sample distribution for evaluation